Received grant in 2020
DCCC has funded 200,000 DKK to the project.
Contemporary imaging techniques with PSMA PET/CT and MRI have enabled an accurate imaging of the tumour localisation within the prostate gland. A growing number of patients go through diagnostic MR of prostate and prostate specific membrane antigen (PSMA) PET/CT when they are diagnosed with prostate cancer. There is a significant potential in more systematically utilising this knowledge in prostate cancer treatment.
The aim is to increase knowledge and expertise within focal therapy of prostate cancer by establishing a Danish national network across professions and hospital units. With the funding from DCCC, the network is to address potentials and risks of tumor directed strategies within the focal therapy field, and further to form essential research questions and develop national clinical research protocols.
Multidisciplinary organisation
DAPROCA – The Danish Prostate Cancer Group
Project stakeholders
Aarhus University Hospital
- Simon Buus, Ph.D., Specialty Registrar, Department of Oncology. Primary contact, Mail: simbuu@rm.dk
- Lise Nørgaard Bentzen, Consultant, Department of Oncology
- Kari Tanderup, Professor, Department of Oncology
- Morten Høyer, Professor, Danish Center for Particle Therapy
- Kirsten Bouchelouche, Consultant, Department of Nuclear Medicine and PET-centre
- Michael Borre, Head of DAPROCA, professor, Department of Urology
- Bodil Ginnerup, Consultant, Department of Radiology
Odense University Hospital
- Mads Hvid Aaberg Poulsen, Specialty Registrar, Department of Urology
Rigshospitalet, Copenhagen
- Peter Meidahl Petersen, Consultant, Department of Oncology
- Klaus Brasso, Professor, Department of Urology
Herlev Hospital
- Henrik Jakobsen, Consultant, Department of Urology
Aalborg University Hospital
- Jimmi Søndergaard, Consultant, Department of Oncology
- Helle Damgaard Zacho, Consultant, Department of Nuclear Medicine
International Panel
- Mark Emberton, Professor, University College London
- Uulke van der Heide, Professor, Netherlands Cancer Institute, Amsterdam
- Alexander Berlin, Princess Margaret Cancer Center, Toronto
- Marco van Vulpen, Professor, Holland Particle Therapy Centre
- Bradley Pieters, Academic Medical Center, Amsterdam